[1]
A. Mjali, M. Obaid, B. Matti, and N. Abbas, “Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq”, apjcc, vol. 7, no. 2, pp. 267-272, Jun. 2022.